Despite the different oncogenic activity in pre-clinical models between p190 and p210, there is no significant difference in terms of clinical outcome following chemotherapy in ALL patients harboring either of the two isoforms (23, 24). This evidence concerns the gene CNTNAP1 and acute lymphoblastic leukemia.